Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
HCSG vs CTAS
Revenue, margins, valuation, and 5-year total return — side by side.
Specialty Business Services
HCSG vs CTAS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Specialty Business Services |
| Market Cap | $1.56B | $68.20B |
| Revenue (TTM) | $1.84B | $10.79B |
| Net Income (TTM) | $59M | $1.90B |
| Gross Margin | 13.3% | 50.2% |
| Operating Margin | 3.0% | 23.0% |
| Forward P/E | 20.3x | 34.6x |
| Total Debt | $25M | $2.65B |
| Cash & Equiv. | $161M | $264M |
HCSG vs CTAS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Healthcare Services… (HCSG) | 100 | 92.3 | -7.7% |
| Cintas Corporation (CTAS) | 100 | 273.2 | +173.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HCSG vs CTAS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
HCSG is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 20 yrs, beta 1.12
- Lower volatility, beta 1.12, Low D/E 4.8%, current ratio 3.38x
- Lower P/E (20.3x vs 34.6x)
CTAS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 7.7%, EPS growth 16.1%, 3Y rev CAGR 9.6%
- 6.9% 10Y total return vs HCSG's -28.2%
- Beta 0.51, yield 0.9%, current ratio 2.09x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.7% revenue growth vs HCSG's 7.1% | |
| Value | Lower P/E (20.3x vs 34.6x) | |
| Quality / Margins | 17.6% margin vs HCSG's 3.2% | |
| Stability / Safety | Beta 0.51 vs HCSG's 1.12 | |
| Dividends | 0.9% yield; 3-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +49.1% vs CTAS's -19.3% | |
| Efficiency (ROA) | 18.7% ROA vs HCSG's 7.3%, ROIC 25.8% vs 9.0% |
HCSG vs CTAS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
HCSG vs CTAS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
CTAS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CTAS is the larger business by revenue, generating $10.8B annually — 5.9x HCSG's $1.8B. CTAS is the more profitable business, keeping 17.6% of every revenue dollar as net income compared to HCSG's 3.2%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.8B | $10.8B |
| EBITDAEarnings before interest/tax | $72M | $2.9B |
| Net IncomeAfter-tax profit | $59M | $1.9B |
| Free Cash FlowCash after capex | $139M | $1.8B |
| Gross MarginGross profit ÷ Revenue | +13.3% | +50.2% |
| Operating MarginEBIT ÷ Revenue | +3.0% | +23.0% |
| Net MarginNet income ÷ Revenue | +3.2% | +17.6% |
| FCF MarginFCF ÷ Revenue | +7.6% | +16.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.6% | +9.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +175.0% | +11.0% |
Valuation Metrics
HCSG leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 26.8x trailing earnings, HCSG trades at a 30% valuation discount to CTAS's 38.5x P/E. On an enterprise value basis, HCSG's 21.7x EV/EBITDA is more attractive than CTAS's 24.7x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.6B | $68.2B |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $70.6B |
| Trailing P/EPrice ÷ TTM EPS | 26.83x | 38.47x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.29x | 34.59x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.30x |
| EV / EBITDAEnterprise value multiple | 21.74x | 24.73x |
| Price / SalesMarket cap ÷ Revenue | 0.85x | 6.60x |
| Price / BookPrice ÷ Book value/share | 3.11x | 14.82x |
| Price / FCFMarket cap ÷ FCF | 11.19x | 38.82x |
Profitability & Efficiency
CTAS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
CTAS delivers a 42.6% return on equity — every $100 of shareholder capital generates $43 in annual profit, vs $12 for HCSG. HCSG carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to CTAS's 0.57x. On the Piotroski fundamental quality scale (0–9), CTAS scores 9/9 vs HCSG's 7/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +11.8% | +42.6% |
| ROA (TTM)Return on assets | +7.3% | +18.7% |
| ROICReturn on invested capital | +9.0% | +25.8% |
| ROCEReturn on capital employed | +7.7% | +29.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 9 |
| Debt / EquityFinancial leverage | 0.05x | 0.57x |
| Net DebtTotal debt minus cash | -$136M | $2.4B |
| Cash & Equiv.Liquid assets | $161M | $264M |
| Total DebtShort + long-term debt | $25M | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | 33.02x | 24.61x |
Total Returns (Dividends Reinvested)
CTAS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CTAS five years ago would be worth $20,172 today (with dividends reinvested), compared to $7,822 for HCSG. Over the past 12 months, HCSG leads with a +49.1% total return vs CTAS's -19.3%. The 3-year compound annual growth rate (CAGR) favors CTAS at 14.2% vs HCSG's 12.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +25.2% | -8.2% |
| 1-Year ReturnPast 12 months | +49.1% | -19.3% |
| 3-Year ReturnCumulative with dividends | +43.8% | +49.1% |
| 5-Year ReturnCumulative with dividends | -21.8% | +101.7% |
| 10-Year ReturnCumulative with dividends | -28.2% | +694.8% |
| CAGR (3Y)Annualised 3-year return | +12.9% | +14.2% |
Risk & Volatility
Evenly matched — HCSG and CTAS each lead in 1 of 2 comparable metrics.
Risk & Volatility
CTAS is the less volatile stock with a 0.51 beta — it tends to amplify market swings less than HCSG's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HCSG currently trades 89.1% from its 52-week high vs CTAS's 73.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 0.51x |
| 52-Week HighHighest price in past year | $24.39 | $229.24 |
| 52-Week LowLowest price in past year | $12.66 | $165.46 |
| % of 52W HighCurrent price vs 52-week peak | +89.1% | +73.8% |
| RSI (14)Momentum oscillator 0–100 | 55.6 | 31.5 |
| Avg Volume (50D)Average daily shares traded | 684K | 2.2M |
Analyst Outlook
HCSG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates HCSG as "Hold" and CTAS as "Hold". Consensus price targets imply 32.0% upside for CTAS (target: $223) vs 12.7% for HCSG (target: $25). CTAS is the only dividend payer here at 0.88% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold |
| Price TargetConsensus 12-month target | $24.50 | $223.40 |
| # AnalystsCovering analysts | 15 | 30 |
| Dividend YieldAnnual dividend ÷ price | — | +0.9% |
| Dividend StreakConsecutive years of raises | 20 | 3 |
| Dividend / ShareAnnual DPS | — | $1.49 |
| Buyback YieldShare repurchases ÷ mkt cap | +4.0% | +1.4% |
CTAS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HCSG leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
HCSG vs CTAS: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is HCSG or CTAS a better buy right now?
For growth investors, Cintas Corporation (CTAS) is the stronger pick with 7.
7% revenue growth year-over-year, versus 7. 1% for Healthcare Services Group, Inc. (HCSG). Healthcare Services Group, Inc. (HCSG) offers the better valuation at 26. 8x trailing P/E (20. 3x forward), making it the more compelling value choice. Analysts rate Healthcare Services Group, Inc. (HCSG) a "Hold" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HCSG or CTAS?
On trailing P/E, Healthcare Services Group, Inc.
(HCSG) is the cheapest at 26. 8x versus Cintas Corporation at 38. 5x. On forward P/E, Healthcare Services Group, Inc. is actually cheaper at 20. 3x.
03Which is the better long-term investment — HCSG or CTAS?
Over the past 5 years, Cintas Corporation (CTAS) delivered a total return of +101.
7%, compared to -21. 8% for Healthcare Services Group, Inc. (HCSG). Over 10 years, the gap is even starker: CTAS returned +694. 8% versus HCSG's -28. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HCSG or CTAS?
By beta (market sensitivity over 5 years), Cintas Corporation (CTAS) is the lower-risk stock at 0.
51β versus Healthcare Services Group, Inc. 's 1. 12β — meaning HCSG is approximately 121% more volatile than CTAS relative to the S&P 500. On balance sheet safety, Healthcare Services Group, Inc. (HCSG) carries a lower debt/equity ratio of 5% versus 57% for Cintas Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — HCSG or CTAS?
By revenue growth (latest reported year), Cintas Corporation (CTAS) is pulling ahead at 7.
7% versus 7. 1% for Healthcare Services Group, Inc. (HCSG). On earnings-per-share growth, the picture is similar: Healthcare Services Group, Inc. grew EPS 52. 8% year-over-year, compared to 16. 1% for Cintas Corporation. Over a 3-year CAGR, CTAS leads at 9. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HCSG or CTAS?
Cintas Corporation (CTAS) is the more profitable company, earning 17.
5% net margin versus 3. 2% for Healthcare Services Group, Inc. — meaning it keeps 17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTAS leads at 22. 8% versus 2. 6% for HCSG. At the gross margin level — before operating expenses — CTAS leads at 50. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HCSG or CTAS more undervalued right now?
On forward earnings alone, Healthcare Services Group, Inc.
(HCSG) trades at 20. 3x forward P/E versus 34. 6x for Cintas Corporation — 14. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CTAS: 32. 0% to $223. 40.
08Which pays a better dividend — HCSG or CTAS?
In this comparison, CTAS (0.
9% yield) pays a dividend. HCSG does not pay a meaningful dividend and should not be held primarily for income.
09Is HCSG or CTAS better for a retirement portfolio?
For long-horizon retirement investors, Cintas Corporation (CTAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
51), 0. 9% yield, +694. 8% 10Y return). Both have compounded well over 10 years (CTAS: +694. 8%, HCSG: -28. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HCSG and CTAS?
These companies operate in different sectors (HCSG (Healthcare) and CTAS (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
CTAS pays a dividend while HCSG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.